The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT ID: NCT00732602
Last Updated: 2009-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of GIP After a Meal in Patients With Type 2 Diabetes
NCT03702660
Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
NCT00603031
GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia
NCT00716170
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B
GLP-2 infusion
GLP-2 infusion
C
Sodium-chloride infusion
Sodium-chloride
A
GIP-infusion
GIP-infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP-infusion
Sodium-chloride
GLP-2 infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Arginine test without rise in plasma C-peptide
* Normal blood Hemoglobin
* Informed consent
Exclusion Criteria
* Diabetic nephropathy
* Treatment with medications unpausable for 12 hours
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital, Gentofte, Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital, Gentofte
Hellerup, Capital Region, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-D-2007-0058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.